Marazzi Fabio, Orlandi Armando, Manfrida Stefania, Masiello Valeria, Di Leone Alba, Massaccesi Mariangela, Moschella Francesca, Franceschini Gianluca, Bria Emilio, Gambacorta Maria Antonietta, Masetti Riccardo, Tortora Giampaolo, Valentini Vincenzo
"A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario, 00168 Roma, Italy.
"A. Gemelli" IRCCS, UOC di Oncologia Medica, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario, 00168 Roma, Italy.
Cancers (Basel). 2020 Aug 24;12(9):2390. doi: 10.3390/cancers12092390.
The standard care for metastatic breast cancer (MBC) is systemic therapies with imbrication of focal treatment for symptoms. Recently, thanks to implementation of radiological and metabolic exams and development of new target therapies, oligometastatic and oligoprogressive settings are even more common-paving the way to a paradigm change of focal treatments role. In fact, according to immunophenotype, radiotherapy can be considered with radical intent in these settings of patients. The aim of this literature review is to analyze available clinical data on prognosis of bone metastases from breast cancer and benefits of available treatments for developing a practical guide for clinicians.
转移性乳腺癌（MBC）的标准治疗是全身治疗并辅以针对症状的局部治疗。最近，由于放射学和代谢检查的实施以及新靶向治疗的发展，寡转移和寡进展状态更为常见，这为局部治疗作用的范式转变铺平了道路。事实上，根据免疫表型，在这些患者情况下可考虑采用根治性放疗。这篇文献综述的目的是分析关于乳腺癌骨转移预后的现有临床数据以及现有治疗的益处，以便为临床医生制定实用指南。
